This approach may offer an immunotherapeutic approach that combines several mutually reinforcing anticancer activities, including delivering the death receptor agonist to the malignant cell population, potent activation of DR5-mediated cell death signaling, and recruitment of Fcγ-receptor-carrying immune cells that can mount an immune response against the tumor cells. The gene discussed is TNFRSF10B; the disease is neoplasm.